2003 NIH Research Festival
<< Back < Home
Mini-Symposia Summary
Link to NIH
Link to General Schedule of Events
Link to Clinical Center 50th Anniversary Symposium
Link to Mini Symposia
Link to Poster Session
Link to Job Fair for NIH Postdoctoral Fellows
Link to Special Exhibits on NIH Intramural Resources
Link to TSA Research Festival Exhibit Show
Link to Festival Food and Music Fair
Link to Research Festival Committee
Mini-symposia Session I
Wednesday, October 15, 2003
Natcher Conference Center
Using the New Omics in the Molecular Epidemiology of Chronic Diseases:
Emergence of a New Paradigm
10:30 a.m. - 12:00 p.m.
Co-chaired by:
Nathaniel Rothman, M.D., M.P.H., M.H.S.
Senior Investigator, Occupational and Environmental Epidemiology Branch,
Division of Cancer Epidemiology and Genetics (DCEG), NCI
Stephen Chanock, M.D.
Head, Section on Genetic Variation, Pediatric Oncology Branch, CCR, NCI and
Director, Core Genotyping Facility, Advanced Technology Center, DCEG, NCI
Balcony A, Natcher Conference Center
New opportunities to explore the etiology of chronic disease, as well as to improve
diagnosis and treatment, have evolved because of new developments in both
technical and analytical approaches to surveying increasingly larger portions of the
expressed proteome and genome. Previously, biologically-based hypothesisdriven
research has been the hallmark of investigating chronic disease but with
the advent of technologies that allow the broad interrogation of the proteome,
transcriptome and genome, essentially the entire range of biologic processes can
now or soon will be analyzed. Though conceptually very exciting, the task of
interpreting the avalanche of information has raised serious questions as to how to
proceed down this course. In particular, the shift in paradigm has altered the
relative importance of testing only hypotheses with high priors. Results from
some of the initial applications of these new technologies will be provided in the
context of cancer research. In addition, the central issues of replication and
validation are undergoing transformation, partly in response to the enormous
amounts of data generated. Specifically, new strategies to minimize the potential
for false-positive findings will be discussed.
Bench-to-Bedside Applications of Clinical Proteomics
Co-directors of the NCI-FDA Clinical Proteomics Program:
Lance A. Liotta, M.D., Ph.D., Chief, Laboratory of Pathology, CCR, NCI
Emanuel F. Petricoin, Ph.D., Senior Principal Investigator, DTP, CBER, FDA
Molecular Diagnosis and Molecular Targets in Cancer by Gene Expression Profiling
Louis M. Staudt, M.D., Ph.D., Chief, Lymphoid Malignancies Section, Metabolism
Branch, CCR, NCI
The Trajectory of Applying Genetic Variation to the Study of the Etiology of Cancer
Stephen Chanock, M.D., Head, Section on Genetic Variation, Pediatric Oncology
Branch, CCR, NCI and Director, Core Genotyping Facility, Advanced Technology
Center, DCEG, NCI
The Problem and Challenge of False Positive Findings in the Omics Era
Sholom Wacholder, Ph.D., Senior Investigator, Biostatistics Branch, DCEG, NCI
    Go to the top